Intriguingly, our results imply that metabolic inhibitors might be most effective on those tumor cells that are otherwise therapy-resistant and that signs of mTOR signaling such as ULK1S757 phosphorylation are potential biomarkers for metabolically vulnerable tumors. This evidence concerns the gene MTOR and neoplasm.